Rosacea: Rosacea is an elusive skin condition. Sufferers of Little Understood Disease May Soon Have New Treatment Options
|
|
- Garry Norris
- 6 years ago
- Views:
Transcription
1 Rosacea: Sufferers of Little Understood Disease May Soon Have New Treatment Options by G. Scott Herron, M.D., Ph.D. Rosacea is an elusive skin condition that is not well understood. Until now, there has been no guaranteed method to eradicate it. However, recent advancements could offer new treatment options for the condition. 62 DERMASCOPE March 2018
2 March 2018 DERMASCOPE 63
3 More than one in 20 American adults approximately 16 million people suffer from rosacea, but this common skin disease is often misdiagnosed as acne. 1 As with acne, there is no simple test to diagnose rosacea. Dermatologists generally identify the condition by observing persistent erythema of the skin in a patient or the emergence of papules or pustules. Unlike acne, people suffering from rosacea are often unaware or confused about the condition. A recent National Rosacea Society (NRS) survey of 1,459 patients 2 found that 95 percent knew little or nothing about rosacea s signs and symptoms prior to their diagnosis and 47 percent said they had never heard of the disease. This lack of awareness increases the threat rosacea poses because some over-the-counter acne treatments that confused rosacea sufferers might use to treat their condition can actually aggravate it. If left untreated, rosacea tends to become more severe with time and can lead to symptoms like permanent ruddiness of the facial skin, thickening of the skin, and even enlargement of the nose. New research shows that rosacea s different symptoms and features may all be part of a continuum of inflammation that may only be detectable 3, 4, 5, 6 histologically and biochemically. For these reasons, rosacea s impact goes beyond the physical. NRS surveys found that more than 90 percent of patients say the condition has lowered their self-confidence and self-esteem, while 41 percent say it has caused them to avoid public contact or cancel social engagements. Among patients with severe symptoms, 88 percent say rosacea has hurt their professional interactions and more than half say it has led them to miss work. 7 WHO IS AT RISK? Fair-skinned adults, especially those with blond hair and blue eyes, are more likely to get rosacea. Particularly susceptible are adults from Celtic or Scandinavian ancestry. 8 An NRS survey of 600 rosacea patients found 42 percent were of Irish, German, or English ancestry. The disease can, however, occur in individuals of any race or skin color. There is also evidence that rosacea may be hereditary. 8 NRS research found that 52 percent of rosacea patients had a relative who suffered from the condition. Age is also a factor. Unlike acne, which typically initially presents in adolescence, 80 percent of cases are diagnosed in people who are at least While women are two to three times more likely than men to get rosacea, men tend to experience more severe cases. 11 Since the onset of the condition tends to occur in adulthood, rosacea achieves highest prevalence in later years. For example, women experience highest prevalence between the ages of 61 and 65. For men, highest prevalence occurs between the ages of 76 and 80. One early warning sign of rosacea may be frequent blushing. Some researchers think rosacea occurs when blood vessels expand too easily, causing blushing. 12 NEW UNDERSTANDING OF ROSACEA There has been an abundance of research since 2002, when the initial classification system of rosacea was developed. At that time, the skin disease was thought to fall into four distinct clinical subtypes with apparently different symptoms. In October 2017, a new classification system was published by the NRS panel of experts. This new grouping system is based on current understanding of the pathophysiology of rosacea and identifies four major phenotypes and three secondary phenotypes of rosacea, all of which appear to be interrelated. 13 MAJOR PHENOTYPES These major phenotypes may occur independently or concurrently. Papules and pustules: Domeshaped, red, acne-like pimples, sometimes accompanied by white heads, often surface in crops across the cheeks 3, 13, and nose. Nodules may also occur. 14, 15, 16 14, 15, DERMASCOPE March 2018
4 Flushing: Frequent and prolonged flushing (sometimes blushing) is common, except in darker skin tones, where flushing may be experienced without obvious erythema. Unlike other erythematous changes, in rosacea, flushing can occur within seconds to minutes in response to neurovascular stimulation by trigger factors.3, 4, 5, 13, 14, 17 Telangiectasia: Telangiectasias, sometimes known as spider veins, are common signs of rosacea and are predominantly centrofacial. Use of a dermatoscope may allow for detection of telangiectasias in patients with darker skin types.13 Ocular manifestations: Ocular rosacea can occur in mild, moderate, or severe cases and may also appear when no other phenotypes are apparent. Signs of ocular rosacea include lid margin telangiectases, interpalpebral conjunctival injection, spade-shaped infiltrates in the cornea, and scleritis and sclerokeratitis. Common symptoms that may suggest ocular rosacea include burning, stinging, light sensitivity, and foreign object sensation.13 SECONDARY PHENOTYPES Burning or stinging: These sensations may occur, normally on erythematous skin without scales, although scaling may also occur.13,18 Pruritus is not a typical characteristic of rosacea, but may also occur. Edema: Facial swelling may accompany or follow prolonged erythema or flushing as a result of postcapillary extravasation during inflammation.19 Soft edema may last for days or be aggravated by inflammatory changes. Solid facial edema (persisting hard, nonpitting edema) can occur with rosacea and independently of redness, papules, pustules, or phymatous changes. Commonly, rosacea-related edema involves a combination of blood and lymphatic vessels.3, 13 Dry appearance: Central facial skin may be rough and scaly, resembling dry skin and suggesting an March 2018 DERMASCOPE 65
5 eczematous dermatitis. Rosacea may coexist with seborrheic dermatitis. The dry appearance may be associated with burning or stinging sensations and may be caused by irritation rather than the disease process.13 Rosacea s different phenotypes may appear in different combinations and at different times, but research suggests that all may be manifestations of the same underlying inflammatory continuum3, 4, 5, 6 and that individual cases may progress in severity and worsen to include additional phenotypes.20, 21 The NRS panel of experts wrote that, recent studies point to a multivariate set of pathogenic pathways, including defects in the innate and adaptive immune systems, mast cells and related biochemical mechanisms, and the neurovascular system. It now appears likely that initial erythema and vascular manifestations such as telangiectasia may be in a continuum initiated by a combination of both neurovascular dysregulation and innate immune responses. 13 The phenotype designations are meant to replace the four subtypes widely used clinically to identify the nature of each patient s rosacea and treat each case. The classical subtypes vascular, inflammatory, rhinophymatous, and ocular rosacea are still used clinically by many dermatologists. However, as the NRS panel s report indicated, they are not accurate diagnostic categories, given the transient and progressive signs and symptoms exhibited by rosacea patients. Earlier research by the NRS had already shown that more than half of rosacea patients suffer from a combination of different subtypes.22 An NRS survey of 1,231 patients found that 72 percent experienced some kind of progression. Overall, 77 percent of patients in the study said they experienced more than one subtype at a time.23 What remains clear is that untreated cases of rosacea generally worsen. CAUSES Beyond the apparent genetic connection, the causes of rosacea are not well understood. Researchers believe there is a relationship between triggers 66 DERMASCOPE March 2018
6 The classical subtypes vascular, inflammatory, rhinophymatous, and ocular rosacea are still used clinically by many dermatologists. However, as the NRS panel s report indicated, they are not accurate diagnostic categories, given the transient and progressive signs and symptoms exhibited by rosacea patients. of rosacea, flushing reaction, and the permanent swelling of blood vessels close to the skin surface (telangiectasis). Inflammation appears to be linked to the flushing reaction, but it is not clear how. NRS experts have called for additional study. 13 Meanwhile, the American Academy of Dermatology reports that researchers are finding important clues about the causes of rosacea: 25 The immune system may play a role. Researchers have found that most people with acnelike rosacea react to a bacterium called bacillus oleronius. The reaction causes their immune systems to trigger an exaggerated inflammatory response. Scientists are not sure this can cause rosacea. A bug that causes intestinal infections may play a role. This bug, Helicobacter pylori, or H. pylori, is common in people who have rosacea. However, because many people who do not suffer from rosacea may have an H. pylori infection, scientists cannot prove it can cause rosacea. A mite that lives on everyone s skin, demodex, may play a role. This mite likes to live on the nose and cheeks, where rosacea often appears. In normal skin, demodex found in small numbers feeds on sebaceous gland contents and is considered part of normal skin microbiome. Studies found that people with rosacea have much larger numbers of demodex mites on their skin. However, some people who do not have rosacea also possess increased facial demodex populations, again indicating it may not cause rosacea, but rather could contribute to abnormal skin physiology characteristic of rosacea. A protein that protects skin from infection, cathelicidin, may cause the redness and swelling. How the body processes this protein may determine whether a person gets rosacea. March 2018 DERMASCOPE 67
7 AVAILABLE TREATMENTS ARE NOT CONSISTENT Subtype 1 erythematotelangiectatic (or vascular) rosacea Subtype 2 papulopustular or inflammatory rosacea Subtype 3 phymatous rosacea Subtype 4 ocular rosacea 68 DERMASCOPE March 2018 Rosacea medications provide inconsistent results; and treatment remains aligned with the four clinical subtypes physicians have used to identify and treat the skin disorder since the early 2000s: Subtype 1, erythematotelangiectatic (or vascular) rosacea: Primary symptoms include flushing and facial redness. Patients of this traditional subtype tend to be sensitive to topical products and cosmetics; so it is best treated by staying out of the sun or using sunscreen. Recently, the FDA approved two topical agents that constrict superficial capillary blood vessels 0.33 percent brimonidine gel and 1 percent oxymetazoline cream. Both agents show temporary improvement in facial redness in rosacea. Subtype 2, papulopustular or inflammatory rosacea: Primary symptoms include persistent redness, papules, or pustules. This subtype has typically been treated with topical or systemic antibiotics or a combination of both. Clinicians usually start with metronidazole cream or gel or topical sulfur/sulfacetamide wash or lotion. Other topical agents found to be effective include azelaic acid (cream and foam) and ivermectin. Two derivatives of tetracycline, minocycline and doxycycline, are the most common systemic treatments for inflammatory rosacea. Subtype 3, phymatous rosacea: Primary symptoms include thickening of the skin and excess tissue that enlarges the nose, a condition known as rhinophyma. This severe form of rosacea generally requires more aggressive therapy and systemic antibiotics, sometimes with isotretinoin. Typically, after maximizing the drug regimen, patients are best served by surgical resurfacing of the rosacea-affected area. Electrosurgery can be used to sculpt the rhinophymatous nose, as can use of a laser. Subtype 4, ocular rosacea: Primary symptoms include eye irritation. Ocular rosacea can only be treated with the use of systemic antibiotics, such as oral tetracycline (250 to 500 milligrams), minocycline (40 to 100 milligrams), or
8 doxycycline (100 milligrams). In some cases, topical corticosteroid eyedrops may help to alleviate symptoms. Most therapies are associated with adverse side effects. For example, in the case of common topicals, patients often complain of itching, burning, and other discomfort. Rosacea sufferers tend to be especially sensitive to skin irritations. In the case of systemic antibiotics, steady use puts patients at risk of antibiotic resistance and adverse systemic events. THE FUTURE Significant research is currently being conducted in rosacea, particularly in papulopustular or inflammatory rosacea, which is, in many ways, a gateway subtype that can lead to more severe cases. Most of the research, 28 of the 43 rosacea studies currently listed on ClinicalTrials.gov, focuses on papulopustular rosacea. Some of these studies are looking at how medical devices may be useful in treating this subtype, but most are evaluating drugs to supplement or supplant existing treatments, which are not curative and often require patients to try several different medications and drug combinations to find an effective treatment.27 Many drugs currently used to treat papulopustular rosacea have significant shortcomings. Metronidazole, a March 2018 DERMASCOPE 69
9 Does a proven antibacterial offer fresh promise for rosacea sufferers? While most drug-related clinical trials in rosacea are focused on existing treatments, two clinical stage companies are researching the efficacy of a proven, widely available, systemic drug reformulated into a treatment for this common skin disease. BioPharmX and Foamix are conducting trials on novel delivery of minocycline, an antibiotic in the tetracycline family that is widely used to treat bacterial and inflammatory skin diseases. While minocycline is less likely to cause bacterial resistance than other -cyclines, physician concern for the growing problem has made many dermatologists reluctant to rely too heavily on oral antibiotics, which tend to flood the body with medicine and have been known to cause adverse effects ranging from nausea to diarrhea. Minocycline, which was first commercialized in 1971, is particularly interesting to dermatologists because it has both antibacterial and anti-inflammatory properties a combination that is useful in the treatment of several skin diseases, including rosacea. However, minocycline has only been available in an oral formulation because drug developers have not been able to stabilize minocycline in a topical formulation, which would allow for targeted delivery directly to the skin. BioPharmX and Foamix are taking different approaches to effectively deliver minocycline through the skin. BioPharmX solubilizes the minocycline in an anhydrous hydrophilic gel formulation. Clinical trials completed to date suggest the minocycline reaches the pilosebaceous unit in the skin where diseases like rosacea and acne form. Foamix, whose formulation suspends minocycline in an oil-based foam, dosed its latest phase 3 clinical trial patient last year. Previous trials have shown their drug also reaches the problem area. Research from BioPharmX and Foamix is particularly interesting because it shows both products dramatically reduce the amount of antibiotic that is measurable in the bloodstream. If ongoing trials confirm the research, the new products may offer significant promise to dermatologists and their patients. cornerstone therapy, has an unknown mechanism of action, but seems to have antimicrobial, antioxidant, and anti-inflammatory properties. 28, 29 It is used topically, but is not as effective as some newer agents. Ivermectin, a recent FDA-approved topical agent to treat papulopustular rosacea, is thought to reduce papules by killing demodex mites that live in the sebaceous glands. 30, 31, 32 However, adverse effects associated with the topical cream include burning, itching, and dryness at the application site. 33 Because of the limitations of current treatments, several companies are researching new twists on existing therapies, such as azelaic acid, an FDAapproved drug found to be effective for papulopustular rosacea. 1, 34 Bayer, Novum Pharmaceutical, and Galderma are researching various formulations of azelaic acid and combinations with other therapies. Galderma is trialing Soolantra and Oracea in combination (Ivermectin 1 percent topical cream and doxycycline 40 milligrams in modified release capsules). Cutanea is researching the efficacy of a topical gel formulation of omiganan a novel, antimicrobial peptide. Two companies are looking at a new approach to rosacea treatment using different delivery systems for minocycline. BioPharmX is conducting trials with a topical minocycline gel that may provide both the antibiotic and anti-inflammatory benefits of this common tetracycline derivative without the systemic adverse effects associated with oral minocycline. Foamix has been researching a foam formulation of the same antibiotic. These topical products have not been approved by the FDA and are still considered investigational (available only for use in clinical trials). While oral doxycycline is commonly used to treat rosacea, oral antibiotics are often associated with systemic adverse effects, such as upset stomach, diarrhea, dizziness, photosensitivity, and headaches. In higher doses, doxycycline also has a greater rate of antibiotic resistance than minocycline. The novel topical formulations of minocycline may have the potential to deliver the efficacy of a tetracycline- 70 DERMASCOPE March 2018
10 class drug without the undesireable systemic effects. Products that are currently in clinical trials may significantly change the way dermatologists treat rosacea in coming years and could potentially reduce adverse effects associated with the treatment. References: Schwab VD, Sulk M, Seeliger S, et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Invest Dermatol Symp Proc. 2011;15: Seeliger S, Buddenkotte J, Schmidt-Choudhury A, et al. Pituitary adenylate cyclase activating polypeptide: an important vascular regulator in human skin in vivo. Am J Pathol. 2010;177: Sulk M, Seeliger S, Aubert J, et al. Distribution and expression of non-neuronal transient receptor potential (TRPV) ion channels in rosacea. J Invest Dermatol. 2012;132: Wladis EJ, Iglesias BV, Adam AP, et al. Molecular biologic assessment of cutaneous specimens of ocular rosacea. Ophthal Plast Reconstr Surg. 2012;28: Mikkelsen C, et. al. Rosacea: Time for a new approach. Forum for Nord Derm Ven. (2017) 22: Spoendlin J, Voegel JJ, Jick SS, Meier CR. A study of the epidemiology of rosacea in the U.K. Br J Dermatol. (2012) Sep;167(3): Brownlee C. Rosacea. Modern Drug Discovery. (2003) Jan; Gallo RL, Granstein RD, et. al. Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol Oct 28. pii: S (17) Steinhoff M, Buddenkotte J, Aubert J, et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Invest Dermatol Symp Proc. 2011;15: Trivedi NR, Gilliland KL, Zhao W, et al. Gene array expression profiling in acne lesions reveals marked upregulation of genes involved in inflammation and matrix remodeling. J Invest Dermatol. 2006;126: Buhl T, Sulk M, Nowak P, et al. Molecular and morphological characterization of inflammatory infiltrate in rosacea reveals activation of Th1/Th17 pathways. J Invest Dermatol. 2015;135: Aubdool AA, Brain SD. Neurovascular aspects of skin neurogenic inflammation. J Invest Dermatol Symp Proc. 2011;15: Lonne-Rahm S-B, Fischer T, Berg M. Stinging and rosacea. Acta Derm Venereol. 1999;79: Steinhoff M, von Mentzer B, Geppetti P, et al. Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol Rev. 2014;94: Tan J, Blume-Peytavi U, et. al. An observational cross-sectional study of rosacea: clinical associations and progression between subtypes. Br J Dermatol Sep;169(3): Holmes AD, Steinhoff M. Integrative concepts of rosacea pathophysiology, clinical presentation and new therapeutics. Exp Dermatol. 2017;26: Rosacea-Time-for-a-New-Approach.pdf rosacea#causes 26 Kligman AM, Christensen MS. Demodex folliculorum: requirements for understanding its role in human skin disease. J Invest Dermatol Jan;131(1): Weinkle AP, Doktor V, Emer J. Update on the management of rosacea. Emer Clin Cosmet Investig Dermatol. 2015;8: doi: /CCID.S Feldman SR, Huang WW, Huynh TT. Current drug therapies 13 for rosacea: a chronic vascular and inflammatory skin disease. J Manag Care Spec Pharm. 2014;20(6): McClellan KJ, Noble S. Topical metronidazole: a review of its use in rosacea. Am J Clin Dermatol. 2000;1(3): doi: / Abokwidir M, Fleischer AB. An emerging treatment: topical ivermectin for papulopustular rosacea. J Dermatolog Treat. 2015;26(4): doi: / Brooks M. FDA clears ivermectin cream (Soolantra) for rosacea. Medscape website. medscape.com/viewarticle/ Published December 24, Accessed December 29, Jarmuda S, O Reilly N, Zaba R, Jakubowicz O, Szkaradkiewicz A, Kavanagh K. Potential role of Demodex mites and bacteria in the induction of rosacea. J Med Microbiol. 2012;61(pt 11): doi: /jmm Del Rosso JQ. Management of cutaneous rosacea: emphasis on new medical therapies. Exert Opin Parmacother. 2014;15(14): doi: / Johnson AW, Johnson SM. The role of topical brimonidine tartrate gel as a novel therapeutic option for persistent facial erythema associated with rosacea. Dermatol Ther (Heidelb). 2015;5(3): doi: /s Dr. Herron is a physician scientist with nearly three decades of dermatology experience and an active clinical practice in Palo Alto, California. As a member of the Stanford University School of Medicine faculty, he conducted biomedical research, consulted with the biopharmaceutical industry, authored or co-authored more than 30 peer-reviewed papers, and secured several patents in the biomedical field. He serves as medical director for BioPharmX Corporation. March 2018 DERMASCOPE 71
Rosacea. This non promotional presentation has been sponsored and developed by Galderma for UK healthcare professionals only.
Rosacea [Speaker Name] [Title] This non promotional presentation has been sponsored and developed by OTH18-07-0214 DOP: September 2018 Learning Objectives To review current guidelines for best practice
More informationRosacea Rosacea: how I hates ya! Richard Castillo, OD, DO The Oklahoma College of Optometry Northeastern State University Tahlequah, OK
Rosacea Rosacea: how I hates ya! Richard Castillo, OD, DO The Oklahoma College of Optometry Northeastern State University Tahlequah, OK Introduction Clinical Features Flushing Telangiectasia Erythema Papules
More informationACNE. Jason M Cheyney, MPAS, PA-C Dermatologic Surgery Specialists Macon, Ga 31211
ACNE Jason M Cheyney, MPAS, PA-C Dermatologic Surgery Specialists Macon, Ga 31211 Pathogenesis of Acne Causative Factors Therapy On the horizon Approximately 45 million Americans have acne It is often
More informationEvidence-based Clinical Practice Guidelines for Treatment of Acne and Rosacea in Canada. Catherine Zip Nov 10, 2016
Evidence-based Clinical Practice Guidelines for Treatment of Acne and Rosacea in Canada Catherine Zip Nov 10, 2016 Acne Acne Classification Type Comedonal Mild-to-moderate papulopustular acne Severe Description
More informationRosacea: a symptom-based approach to management Edward Seaton MA, MRCP
Rosacea: a symptom-based approach to management Edward Seaton MA, MRCP VM Rosacea is a common skin condition of unknown aetiology. Dr Seaton describes the recommended management of the vascular and inflammatory
More informationRelevant Disclosures. Investigator/Consultant-Allergan. Investigator-Galderma
Rosacea Update 2018 Lawrence J Green, MD Associate Clinical Professor Department of Dermatology George Washington University School of Medicne Washington DC Relevant Disclosures Investigator/Consultant-Allergan
More informationUpdate of Rosacea. Case 1. Case 2 8/15/2017
Update of Rosacea Dr Samantha Eisman Dermatologist Sinclair Dermatology MBChB MRCP(UK) FCDerm(SA) FACD Case 1 Your 55 year old cousin calls and asks advise about her red face. What is your differential
More informationCUTIS. Although recommendations on the management. Do Not Copy
Consensus Recommendations From the American Acne & Rosacea Society on the Management of Rosacea, Part 5: A Guide on the Management of Rosacea James Q. Del Rosso, DO; Diane Thiboutot, MD; Richard Gallo,
More informationCorporate Medical Policy
Corporate Medical Policy Non-Pharmacologic Treatment of Rosacea File Name: Origination: Last CAP Review: Next CAP Review: Last Review: non-pharmacologic_treatment_of_rosacea 8/2005 11/2017 11/2018 11/2017
More informationX-Plain Acne Reference Summary
X-Plain Acne Reference Summary Nearly 17 million people in the United States have acne, making it one of the most common skin diseases in the USA. Although acne is not a serious health threat, severe acne
More information资料来自互联网, 仅供科研和教学使用, 使用者请于 24 小时内自行删除
Clinical dermatology Original article CED Clinical and Experimental Dermatology A comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea:
More informationDermatologists who keep an open mind and tailor the regimen to each individual can help steer patients toward long-term control of rosacea symptoms.
Dermatologists who keep an open mind and tailor the regimen to each individual can help steer patients toward long-term control of rosacea symptoms. By Paul Winnington, Editor-in-Chief 48 Practical Dermatology
More informationThough it represents one of the more commonly seen
The marriage of standard rosacea therapies and light-based interventions sets the bar for successful rosacea therapy. By David F. Horne, MD and Diane S. Berson, MD Though it represents one of the more
More informationAN EDUCATIONAL SUPPLEMENT BEST PRACTICES IN THE TREATMENT ROSACEA SUPPORTED BY
AN EDUCATIONAL SUPPLEMENT BEST PRACTICES IN THE TREATMENT OF ROSACEA SUPPORTED BY 2 Best Practices in the Treatment of Rosacea FACULTY & DISCLOSURES PANELISTS Hilary Baldwin, MD, is a board-certified dermatologist
More informationTime to Learn. 6 th March 2018 Dr. Shirin Chakera GPwSI Integrated Dermatology Service
Time to Learn 6 th March 2018 Dr. Shirin Chakera GPwSI Integrated Dermatology Service The Red Face Rosacea Acne Seborrhoeic eczema eczema Psoriasis Slapped cheek syndrome Fungal infection Erysipelas...
More informationDoxycycline/Minocycline Step Therapy Criteria Program Summary
This criteria applies to Commercial, NetResults F series and Health Insurance Marketplace formularies. OBJECTIVE The intent of the Doxycycline/Minocycline Step Therapy (ST) program is to encourage the
More informationReview patient presentations and pathophysiology. Discuss Treatment options Tried and true New and upcoming. Prevention and Counselling
Speaker: Janssen Consultant: Valeant, Allergan Drinker: Stone, Pizza Port, Lost Abbey Review patient presentations and pathophysiology Discuss Treatment options Tried and true New and upcoming Prevention
More informationCutaneous rosacea: a thorough overview
32 Cutaneous rosacea: a thorough overview of pathogenesis, clinical presentations, and current recommendations on management James Q. Del Rosso Del Rosso Dermatology Research Center Las Vegas, Nevada The
More informationTo order reprints or e-prints of JDD articles please contact JDD
June 2017 534 VOLUME 16 ISSUE 6 Copyright 2017 ORIGINAL ARTICLE Journal of Drugs in Dermatology The Efficacy and Safety of Azelaic Acid 15% Foam in the Treatment of Truncal Acne Vulgaris Lauren K. Hoffman
More information..GAL D ERMA. Swiss Summary of the Risk Management Plan for Soolantra (ivermectin cream lomg/g) Galderma International
Page 1 of7 Swiss Summary of the Risk Management Plan for Soolantra (ivermectin cream lomg/g) Galderma International Version Number: 1.0 Document Date: 16-February-2017 Page 2 of7 Summary of the Risk Management
More informationF r e q u e n t l y A s k e d Q u e s t i o n s
Acne who specializes in treating skin problems) about how you can help prevent acne and if treatment would help you. Q: What is acne? A: Acne is a disorder that causes outbreaks of skin lesions commonly
More informationAdvanced facials Week 1A T1 2016
Advanced facials Week 1A T1 2016 Sensitive skin Erythemic skin Sensitivity Characteristics Reacts to external stimuli by becoming red/blotchy More easily irritated Most often fair / red hair History of
More informationRosacea Management. Review Article
Review Article Received: February 23, 2016 Accepted: April 14, 2016 Published online: May 18, 2016 Rosacea Management Manal Abokwidir Steven R. Feldman Department of Dermatology, Center for Dermatology
More informationRosacea Update: Rosacea pathogenesis. Rosacea genetics. Disclosures. Rosacea: Etiology? Th1/Th17 is activated in rosacea skin
Winter Clinical Big Island 20 min Rosacea Update: 2017 Diane M. Thiboutot, M.D. Professor of Dermatology The Pennsylvania State University College of Medicine Hershey, PA Disclosures Investigator or consultant
More informationACNE BOOT CAMP TOPICAL THERAPY BASICS
ACNE BOOT CAMP TOPICAL THERAPY BASICS Lawrence J Green, MD Associate Clinical Professor of Dermatology George Washington University School of Medicine Washington DC Relevant Disclosures Investigator -Allergan,
More informationOriginal Policy Date
MP 2.01.45 Non-Pharmacologic Treatment of Rosacea Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to Medical
More informationACNE. What are the aims of this leaflet?
ACNE What are the aims of this leaflet? This leaflet has been written to help you understand more about acne - what it is, what causes it, what can be done about it and where you can find out more about
More informationINTRODUCTION. Printed in Great Britain. Correspondence Kevin Kavanagh Received 8 June 2013 Accepted 15 November 2013
Journal of Medical Microbiology (214), 63, 258 262 DOI 1.199/jmm..65136- Correlation between serum reactivity to Demodexassociated Bacillus oleronius proteins, and altered sebum levels and Demodex populations
More informationPRODUCT MONOGRAPH TABLE OF CONTENTS. p. 8 p. 12
PRODUCT MONOGRAPH PRODUCT MONOGRAPH TABLE OF CONTENTS p. 8 p. 12 2 OVERVIEW OF ROSACEA Rosacea is a chronic skin disease with a relapsing-remitting course characterized by a variable spectrum of dermatologic
More informationAcne vulgaris is a disease of the pilosebaceous unit (i.e., the sebaceous glands and adjacent hair follicle).
Dr. Ghassan Salah Acne is a common, chronic inflammatory disorder of the pilosebaceous unit in which a microcomedo develops as the initial condition. The most common form of acne is acne vulgaris. Other
More informationACNE UPDATE 2017 FACULTY DISCLOSURE ACNE UPDATE
ACNE UPDATE 2017 PATRICIA TREADWELL, M.D. PROFESSOR OF PEDIATRICS AND DERMATOLOGY IU SCHOOL OF MEDICINE FACULTY DISCLOSURE I have no relevant financial relationships with the manufacturer(s) of any commercial
More informationPulsed Dye Laser Treatment Combined with Oral Minocycline Reduces Recurrence Rate of Rosacea
pissn 1013-9087ㆍeISSN 2005-3894 Ann Dermatol Vol. 29, No. 5, 2017 https://doi.org/10.5021/ad.2017.29.5.543 ORIGINAL ARTICLE Pulsed Dye Laser Treatment Combined with Oral Minocycline Reduces Recurrence
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 January 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 January 2012 EPIDUO, gel Tube of 30 g (CIP code: 383 814-6) Tube of 60 g (CIP code: 383 816-9) Applicant: GALDERMA
More informationA Novel Approach for Acne Treatment
A Novel Approach for Acne Treatment E.V. Ross, M.D.; M.A. Blair, M.D.; B.S. Graham, M.D.; Naval Medical Center, San Diego, CA D.Y. Paithankar, Ph.D.; B.A. Saleh, M.Eng.; Candela Corporation, Wayland, MA
More informationDoxycycline/Minocycline Step Therapy Criteria Program Summary
Doxycycline/Minocycline Step Therapy Criteria Program Summary Step therapy applies to Commercial and Health Insurance Marketplace formularies only. OBJECTIVE The intent of the Doxycycline/Minocycline Step
More informationAzelaic Acid 15% Gel: The Versatile Foundation of Combination Therapy in Mild to Moderate Rosacea in Various Patient Types COS DERM
Review Azelaic Acid 15% Gel: The Versatile Foundation of Combination Therapy in Mild to Moderate Rosacea in Various Patient Types Jeanine Downie, MD Rosacea is a common, chronic dermatologic condition
More informationRosacea is a chronic, inflammatory skin disease that affects primarily
The new england journal of medicine Caren G. Solomon, M.D., M.P.H., Editor Rosacea Esther J. van Zuuren, M.D. This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) September 2014 Review date: September 2017 Bulletin 204 : Brimonidine tartrate gel (Mirvaso ) for the treatment of facial erythema of rosacea in
More informationSTUDY. A Comparison of 15% Azelaic Acid Gel and 0.75% Metronidazole Gel in the Topical Treatment of Papulopustular Rosacea
A Comparison of 15% Azelaic Acid Gel and 0.75% Metronidazole Gel in the Topical of Papulopustular Rosacea Results of a Randomized Trial STUDY Boni E. Elewski, MD; Alan B. Fleischer, Jr, MD; David M. Pariser,
More informationThe skin is the largest organ of the human body. Functions: protection sensation maintain temperature vitamin synthesis
Dermatology The skin is the largest organ of the human body. Functions: protection sensation maintain temperature vitamin synthesis The image to the left shows an image of skin cells and the proteins which
More informationInteresting Case Series. Rhinophyma
Interesting Case Series Rhinophyma Jake Laun, BS, Jared Gopman, BS, Joshua B. Elston, MD, and Michael A. Harrington, MD Department of Surgery, Division of Plastic Surgery, University of South Florida Morsani
More informationPrevalence of Demodex Species Infestation in Patients with And Without Scaly Blepharitis
January, 2019 2019; Vol3; Issue 1 http://iamresearcher.online Prevalence of Demodex Species Infestation in Patients with And Without Scaly Blepharitis Ezhil vathani 1, Venmani. M 2, Malini. R 3 1 Department
More informationClinical indicators of rosacea progression: a topographic evaluation according to subtype and severity
Hong Kong J. Dermatol. Venereol. (2017) 25, 161-169 Original Article Clinical indicators of rosacea progression: a topographic evaluation according to subtype and severity JS Hong, G Jo, HS Park, HS Yoon,
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationSudden Appearance of Indurated Erythematous Plaques on a Man's Face
Touro College and University System Touro Scholar NYMC Student Publications Students 2016 Sudden Appearance of Indurated Erythematous Plaques on a Man's Face Adam Carter New York Medical College Karthikeyan
More informationNEHSNORTH EASTERN HEALTH SPECIALISTS
COSMETIC DERMATOLOGY NEHSNORTH EASTERN HEALTH SPECIALISTS nehs.com.au CONSENT FORM VASCULAR Treatment with BBL & LASERS I, DOB:, of authorize of North Eastern Health Specialist to perform hair removal
More informationLMMG New Medicine Recommendation
LMMG New Medicine Recommendation Brimonidine (Mirvaso ) gel for facial erythema of rosacea in adults 18 years and over LMMG Recommendation: BLACK Brimonidine gel is not recommended for use to treat symptomatic
More informationScheffer C.G. Tseng, MD, PhD
Demodex: when mites are causing your eye irritation? Scheffer C.G. Tseng, MD, PhD Table of Contents Chapter 1: Introduction Chapter 2: Eye Mites? Gross! What are They? And What Do They Do? Chapter 3: Are
More informationRosacea is a common, but often
Rosacea: A Common, Yet Commonly Overlooked, Condition B. WAYNE BLOUNT, M.D., M.P.H., and ALLEN L. PELLETIER, M.D. University of Tennessee Health Science Center, Memphis, Tennessee Rosacea is a common,
More informationFigure 7.1 Figure 7.2 Figure 7.3
CASE 7 Patient: A 63 year-old Thai female from Pathumthani Chief Complaint: Progressive facial eruption in 1 month Present Illness: The lesions involved only facial area without itching or pain. No associated
More informationبالدويدات الشعرية الاجربة التهاب= Demodex folliculitis. Rosacea
Rosacea ROSACEA Despite universal recognition, rosacea remains a controversial topic in dermatology, largely because of its uncertain pathophysiology and clinical variation. Practitioners and the public
More informationInvasive Pulsed-Type, Bipolar, Alternating Current Radiofrequency Treatment Using Microneedle Electrodes for Nasal Rosacea
Med Laser 2017;6(1):32-36 https://doi.org/10.25289/ml.2017.6.1.32 pissn 2287-8300 ㆍ eissn 2288-0224 Invasive Pulsed-Type, Bipolar, Alternating Current Radiofrequency Treatment Using Microneedle Electrodes
More informationTopical Ivermectin in the Treatment of Papulopustular Rosacea: A Systematic Review of Evidence and Clinical Guideline Recommendations
Dermatol Ther (Heidelb) (2018) 8:379 387 https://doi.org/10.1007/s13555-018-0249-y REVIEW Topical Ivermectin in the Treatment of Papulopustular Rosacea: A Systematic Review of Evidence and Clinical Guideline
More informationA case of rosacea fulminans in a pregnant woman
Hong Kong J. Dermatol. Venereol. (2018) 26, 122-126 Views and Practice A case of rosacea fulminans in a pregnant woman JE Seol, SH Park, JU Kim, GJ Cho, SH Moon, H Kim Introduction Rosacea fulminans (RF)
More informationNovan Announces Promising Clinical Results with SB414
Novan Announces Promising Clinical Results with SB414 In the recently completed Phase 1b trial for atopic dermatitis, clinical efficacy measures were highly correlated with critical and disease-relevant
More information! Alcon! Carl Zeiss Meditec! Reichert! Thrombogenics! Zeavision! Kemin. ! CE Companies:
ROSACEA REVIEW Joseph J. Pizzimenti, OD, FAAO Associate Professor Nova Southeastern University pizzimen@nova.edu Financial Disclosure! Dr. Pizz has received honoraria from, participated in paid advisory
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationManagement of Truncal Acne Vulgaris: Current Perspectives on Treatment
DRUG THERAPY TOPICS Management of Truncal Acne Vulgaris: Current Perspectives on Treatment James Q. Del Rosso, DO Acne vulgaris is one of the most common disorders encountered by dermatologists in the
More informationPresented by: Adelaide A Hebert, MD UTHealth McGovern Medical School, Houston, TX
Evaluation of the Efficacy, Safety and Tolerability of 4% Once-Daily in Subjects with Moderate to Severe Acne Vulgaris Treated Topically for Up to 52 Weeks A Hebert, J Del Rosso, M Rico, R Woolson, E de
More informationROSACEA. ETIOLOGICAL ASPECTS AND STAGING
Analele Universităţii din Oradea, Fascicula Protecţia Mediului Vol. XXVI 2016 ROSACEA. ETIOLOGICAL ASPECTS AND STAGING Bonta Marinela*, Bud Corina** *University of Oradea, Faculty of Medicine and Pharmacy,
More informationCHANGING THE FACE OF ROSACEA MANAGEMENT
A SUPPLEMENT TO Skin & Allergy News CHANGING THE FACE OF ROSACEA MANAGEMENT Chair Henry H. Roenigk, Jr., MD Professor Emeritus Northwestern University Medical School Arizona Advanced Dermatology Scottsdale
More informationNovan Provides Update on SB414 Inflammatory Skin Disease Development Program
Novan Provides Update on SB414 Inflammatory Skin Disease Development Program SB414 Nitric Oxide-Releasing Cream Safe and Well-Tolerated in Psoriasis Phase 1b Trial Preclinical Data with SB414 Targeting
More informationROSACEA IS A CHRONIC CUTAneous. Cutaneous and Ocular Signs of Childhood Rosacea STUDY
STUDY Cutaneous and Ocular Signs of Childhood Rosacea Mélanie Chamaillard, MD; Bruno Mortemousque, MD; Franck Boralevi, MD; Claudia Marques da Costa, MD; Farida Aitali, MD; Alain Taïeb, MD; Christine Léauté-Labrèze,
More informationEFFICACY AND SAFETY OF CLOBETASOL PROPIONATE SHAMPOO IN THERAPY OF PSORIASIS OF THE SCALP
WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Platonova et al. SJIF Impact Factor 2.786 Volume 4, Issue 04, 238-246. Research Article ISSN 2278 4357 EFFICACY AND SAFETY OF CLOBETASOL PROPIONATE
More informationSHEPROS PIMPLE GEL. SHEPROS Sdn. Bhd. [An Alliance of SHEPROS International (USA) LLC.] Safety, Heath & Environment Product Solutions
SHEPROS Safety, Heath & Environment Product Solutions PIMPLE GEL SHEPROS Sdn. Bhd. [An Alliance of SHEPROS International (USA) LLC.] Pimples What are pimples? A pimple is a small pustule or papule. Pimples
More informationMedical Dermatology Highlights Eric Hossler, MD Program Director, Dermatology Associate, Dermatopathology Geisinger Medical Center
Medical Dermatology Highlights 2017 Eric Hossler, MD Program Director, Dermatology Associate, Dermatopathology Geisinger Medical Center I have no relevant financial relationships with commercial interest(s).
More informationDD PROOFS. Acne vulgaris is a multifactorial skin disorder affecting
June 2014 611 Copyright 2014 ORIGINAL ARTICLES SPECIAL TOPIC Rapid Treatment of Mild Acne With a Novel Skin Care System Containing 1% Salicylic Acid, 10% Buffered Glycolic Acid and Botanical Ingredients
More informationExfoliation. Renew and Re-youth With. Illuminate Individuality: Acne Fall Color Preview. and Skin of Color.
www.skininc.com SEPTEMBER 2014 SEPTEMBER 2014 Illuminate Individuality: 2014 Fall Color Preview Acne and Skin of Color Renew and Re-youth With Exfoliation Treating Acne in By Jennifer Linder, MD Skin of
More informationYou Asked for It! CE. Rosacea: Understanding the Patient Journey, Offering Insightful Help
You Asked for It! CE AN ONGOING CE PROGRAM of the University of Connecticut School of Pharmacy EDUCATIONAL OBJECTIVES After participating in this activity pharmacists will be able to: Discuss rosacea's
More informationIntroduction. Crowded environments where the air is re-circulated can often be heavily infected with unseen germs and viruses.
Introduction The continued increase in urbanisation,, population growth and global travel means germs and viruses can spread faster and further than ever before. Air, sea, rail and road travel have never
More informationSkin Cancer of the Nose: Common and Uncommon
Skin Cancer of the Nose: Common and Uncommon Mark Russell, M.D. Associate Professor of Dermatology, Otolaryngology, and Pathology University of Virginia Objectives Review clinical presentations of select
More informationACNE THERAPY Experience with Palomar LuxV Intense Pulsed Light Therapy
ACNE THERAPY Experience with Palomar LuxV Intense Pulsed Light Therapy Robert S. Berger, MD, FAAD, FASDS., Assistant Professor, Department of Dermatology, The Johns Hopkins University, Baltimore, Private
More informationWorld Journal of Pharmaceutical Research
Shraddhamayananda SJIF Impact Factor 5.045 Volume 3, Issue 6, 618-625. Research Article ISSN 2277 7105 EFFICACY OF HOMEOPATHIC MEDICINES IN THE TREATMENT OF ACNE *Swami Shraddhamayananda Ramakrishna Mission
More informationCore Safety Profile. Pharmaceutical form(s)/strength: solution 1%, spray 1%, cream 1%, gel 1% SK/H/PSUR/0005/001 Date of FAR:
Core Safety Profile Active substance: Terbinafine Pharmaceutical form(s)/strength: solution 1%, spray 1%, cream 1%, gel 1% P-RMS: SK/H/PSUR/0005/001 Date of FAR: 08.06.2012 4.3 Contraindications Hypersensitivity
More informationWhat causes pimples in the first place? Dr. Melissa K. Levin, a board-certified dermatologist, breaks it down for us:
Ah, acne something that s plagued many of us during our teenage years, or may still be plaguing us currently as adults. Whether we re blessed to deal with a nose full of blackheads or more serious, painful,
More informationAcne is the most common PSU disorder which develops when the pores of the PSU get blocked.
Published on: 7 Nov 2010 Acne: Overview Introduction Acne, more commonly called as pimples: is the most common skin disorder seen in adolescence. Spontaneous regression usually occurs after 20 years of
More informationNext Generation in Acne treatment. A new approach in Acne Treatment. GramaDerm. Advanced Acne Vulgaris Management with Microcyn Technology
Next Generation in Acne treatment A new approach in Acne Treatment GramaDerm Advanced Acne Vulgaris Management with Microcyn Technology Did you know? 85% of young people between the ages of 12 and 24 years
More informationTwo Cases of Corneal Ulcer Caused by Ocular Rosacea: Late Versus Prompt Diagnosis and Treatment
JOURNAL OF CASE REPORTS 2016;6(2):263-267 Two Cases of Corneal Ulcer Caused by Ocular Rosacea: Late Versus Prompt Diagnosis and Treatment Anandita Widya, Susiyanti Made Infection and Immunology Division,
More informationOral Azithromycin Pulse Therapy and Daily Topical Benzoyl Peroxide in the Treatment of Acne Vulgaris: An Open Clinical Trial Study
Journal of Bangladesh College of Physicians and Surgeons Vol. 36, No. 1, January 218 Oral Azithromycin Pulse Therapy and Daily Topical Benzoyl Peroxide in the Treatment of Acne Vulgaris: An Open Clinical
More informationMulti-Application Platform. Summary of Peer-reviewed Articles for Various Clinical Indications April 2016
Multi-Application Platform Summary of Peer-reviewed Articles for Various Clinical Indications April 2016 Various Clinical Indications Atrophic acne scars and acne Photo-aged skin, pigmentation & hyperpigmentation
More informationACNE VULGARIS: DIAGNOSIS AND TREATMENT
ACNE VULGARIS: DIAGNOSIS AND TREATMENT Federal Bureau of Prisons Clinical Guidance DECEMBER 2017 Clinical guidance is made available to the public for informational purposes only. The Federal Bureau of
More informationTreatment of Refractory Rosacea with a Dual Wavelength Long- Pulsed 755-nm Alexandrite and 1,064-nm Nd:YAG Laser
Med Laser 2018;7(1):47-51 https://doi.org/10.25289/ml.2018.7.1.47 pissn 2287-8300 ㆍ eissn 2288-0224 Treatment of Refractory Rosacea with a Dual Wavelength Long- Pulsed 755-nm Alexandrite and 1,064-nm Nd:YAG
More informationTCIs are only available on prescription and are usually started by a dermatology specialist.
(TCIs) What are topical calcineurin inhibitors? Topical calcineurin inhibitors are treatments that alter the immune system and have been developed for controlling eczema. There are two types available:
More informationRadiation Therapy. This reference summary reviews what to expect during and after radiation therapy.
Radiation Therapy Introduction Radiation therapy is a very common treatment for a variety of cancers. Radiation therapy, also called radiotherapy, is a cancer treatment that uses high doses of radiation
More informationUpdates in the Management of Epidermal Growth Factor Receptor (EGFR) Inhibitors- Induced Skin Rash. Outline. Signal Transduction
Updates in the Management of Epidermal Growth Factor Receptor (EGFR) Inhibitors- Induced Skin Rash Siu-Fun Wong, PharmD, FASHP, FCSHP Associate Professor of Pharmacy Practice Western University of Health
More informationLaser Treatment of Acne and Rosacea
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationPapulopustular rosacea and rosacea-like demodicosis: two phenotypes of the same disease?
DOI: 10.1111/jdv.14885 JEADV ORIGINAL ARTICLE Papulopustular rosacea and rosacea-like demodicosis: two phenotypes of the same disease? F.M.N. Forton, 1, * V. De Maertelaer 2 1 Dermatology Clinic, Brussels,
More informationPrevention. Skin cancer is the most common cancer in the. The Science of. by Laura Brockway-Lunardi, Ph.D.
66 DERMASCOPE June 2012 The Science of Prevention by Laura Brockway-Lunardi, Ph.D. Skin cancer is the most common cancer in the U.S. with more than two million Americans diagnosed annually. Basal cell
More informationPRE-CARE & POST CARE FOR ALL TREATMENTS
PRE-CARE & POST CARE FOR ALL TREATMENTS Laser Hair Removal If this is your first visit to Sedo Laser, please arrive 15 minutes prior to your appointment to complete new client paperwork. Please come with
More informationRosacea is a common dermatologic disorder
Pediatric Dermatology A Phase 3 Randomized, Double-blind, Vehicle-Controlled Trial of Azelaic Acid Foam 15% in the Treatment of Papulopustular Rosacea Zoe Diana Draelos, MD; Boni E. Elewski, MD; Julie
More informationThursday 21 st August Skin Problems
Thursday 21 st August 2014 Skin Problems Skin Problems The Sun and the Skin Sun Damage Recognising the early signs of skin cancer The Big 3 inflammatory condi=ons Acne & Rosacea Eczema (Including Seborrhoeic
More informationNasolacrimal Duct Blockage
The eyelids play a key role in protecting the eyes. They help spread moisture (tears) over the surface of the eyes when they close (for example, while blinking); thus, they help prevent the eyes from becoming
More informationRedness and Rosacea YOLANDA R. HELFRICH, M.D. ASSOCIATE PROFESSOR DEPARTMENT OF DERMATOLOGY
Redness and Rosacea YOLANDA R. HELFRICH, M.D. ASSOCIATE PROFESSOR DEPARTMENT OF DERMATOLOGY DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY Yolanda Rosi Helfrich, MD F135: Redness and Rosacea DISCLOSURES
More informationTable of Contents. Injectable Gel with 0.3% Lidocaine
Patient Brochure Table of Contents About Restylane-L 4 Safety 6 Post-Marketing Surveillance 9 About the Procedure 10 Troubleshooting 11 Injectable Gel with 0.3% Lidocaine 2 3 About Restylane-L Q What is
More informationDermatology for the PCP
Dermatology for the PCP Laura S. Winterfield, MD MPH Associate Professor Medical University of South Carolina I have no relevant conflicts of interest. 1 Learning Objectives Identify common skin conditions
More informationPlease note that this information leaflet is for men, there is a separate information leaflet for women.
ISOTRETINOIN - MALE Please note that this information leaflet is for men, there is a separate information leaflet for women. What are the aims of this leaflet? This leaflet has been written to help you
More informationThe future of Skin Cancer Treatment
The future of Skin Cancer Treatment What is ZaicaDerm? Fully formulated cream that delivers Tea Tree Oil in a transdermal format Using proprietary technology, ZaicaDerm, delivers 10% Tea Tree Oil below
More information